1,2,3,4-Tetrahydroisoquinoline

1,2,3,4-Tetrahydroisoquinoline

SCHEMBL987515

Cl.c1ccc2c(c1)CCNC2

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of 1,2,3,4-Tetrahydroisoquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAOB known ✓ P27338 1/20 0.95
HTR2C known ✓ P28335 1/20 0.71
ADRA2A known ✓ P08913 1/20 0.52
ADRA2B known ✓ P18089 1/20 0.52
ADRA2C known ✓ P18825 1/20 0.52
PNMT P11086 5/20 0.95
CD44 P16070 2/20 0.95
ASIC3 Q9UHC3 1/20 0.52
PRCP P42785 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 1.00 PNMT (0.95) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL29457586 1.00 PNMT (0.95) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL8904839 0.98 PNMT (0.91) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL9815336 0.98 PNMT (0.91) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 0.97 PNMT (1.00) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 0.97 PNMT (1.00) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 0.97 PNMT (1.00) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL4243903 0.95 PNMT (0.95) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL20524019 0.95 PNMT (0.95) PNMTCD44MAOBHTR2CADRA2A
1,2,3,4-Tetrahydroisoquinoline SCHEMBL2082936 0.95 PNMT (0.95) PNMTCD44MAOBHTR2CADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112500343-B Synthesis method of 5, 7-dichloro-1, 2,3, 4-tetrahydroisoquinoline hydrochloride 山东金城柯瑞化学有限公司 2023-04-07 CN claimed
CN-108926564-A A kind of nondepolarizing muscle relaxant composition and its preparation method and application 四川科瑞德制药股份有限公司 2018-12-04 CN claimed
CN-102302781-A Medical use of inhibitors of glutaminyl and glutamate cyclases PROBIODRUG AG 2012-01-04 CN claimed
EP-1784404-A4 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2009-09-09 EP claimed
JP-2008511621-A 2008-04-17 JP claimed
EP-1784404-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2007-05-16 EP claimed
WO-2006025716-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2006-03-09 WO claimed
US-20040248310-A1 Method for detection of bromine in urine using liquid chemistry, dry chemistry test pads, and lateral flow SMITH JACK V (US) 2004-12-09 US claimed
US-20030186451-A1 Method for detection of bromine in urine using liquid chemistry, dry chemistry test pads. and lateral flow SMITH JACK V (US) 2003-10-02 US claimed
US-6537823-B1 Use in determination of adulterants in illicit drug screening samples as a means of detecting false negative results SCITECK DIAGNOSTICS, INC. 2003-03-25 US claimed
WO-2001002368-A1 N-HETEROCYCLIC DERIVATIVES WITH NEURONAL ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-01-11 WO claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0914332-A1 ISOQUINOLINES USEFUL AS ANALGESICS Astra Aktiebolag (SE) 1999-05-12 EP claimed
WO-1997031940-A1 ISOQUINOLINES USEFUL AS ANALGESICS ASTRA AKTIEBOLAG (SE) 1997-09-04 WO claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0232989-B1 ISOQUINOLINE DERIVATIVES Dr. Lo. Zambeletti S.p.A. (IT) 1991-08-21 EP claimed